guest ::
| Home > Publications database > The atypical chemokine receptor 2 limits progressive fibrosis after acute ischemic kidney injury. > print |
| Home > Publications database > The atypical chemokine receptor 2 limits progressive fibrosis after acute ischemic kidney injury. > print |
| 001 | 141759 | ||
| 005 | 20240229112526.0 | ||
| 024 | 7 | _ | |a 10.1016/j.ajpath.2018.09.016 |2 doi |
| 024 | 7 | _ | |a pmid:30448408 |2 pmid |
| 024 | 7 | _ | |a 0002-9440 |2 ISSN |
| 024 | 7 | _ | |a 1525-2191 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2018-02028 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Lux, Moritz |b 0 |
| 245 | _ | _ | |a The atypical chemokine receptor 2 limits progressive fibrosis after acute ischemic kidney injury. |
| 260 | _ | _ | |a New York [u.a.] |c 2019 |b Elsevier |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1552304946_14447 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Following renal ischemia-reperfusion injury (IRI) resolution of inflammation allows tubular regeneration, whereas ongoing inflammatory injury mediated by infiltrating leukocytes leads to nephron loss and renal fibrosis, typical hallmarks of chronic kidney disease. The atypical chemokine receptor 2 (ACKR2) is a chemokine decoy receptor, that binds and scavenges inflammatory CC-chemokines and reduces local leukocyte accumulation. We hypothesized that ACKR2 limits leukocyte infiltration, inflammation, and fibrotic tissue remodeling after renal IRI, thus preventing progression to chronic kidney disease. Compared to wild-type, Ackr2 deficiency increased CC chemokine ligand 2 levels in tumor necrosis factor-stimulated tubulointerstitial tissue in vitro. In Ackr2-deficient mice with early IRI one or five days after transient renal pedicle clamping tubular injury was similar to wild-type, although accumulation of mononuclear phagocytes increased in postischemic Ackr2-/- kidneys. Regarding long-term outcomes, Ackr2-/- kidneys displayed more tubular injury five weeks after IRI, which was associated with persistently increased renal infiltrates of mononuclear phagocytes, T cells, Ly6Chigh inflammatory macrophages, and inflammation. Moreover, Ackr2 deficiency resulted in substantially aggravated renal fibrosis in Ackr2-/- kidneys five weeks after IRI, as revealed by increased expression of matrix molecules, renal accumulation of αSMA+ myofibroblasts, and bone marrow-derived fibrocytes. ACKR2 plays an important role in limiting persistent inflammation, tubular loss, and renal fibrosis after ischemic acute kidney injury, and thus can prevent progression to chronic renal disease. |
| 536 | _ | _ | |a 317 - Translational cancer research (POF3-317) |0 G:(DE-HGF)POF3-317 |c POF3-317 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Blaut, Alexander |b 1 |
| 700 | 1 | _ | |a Eltrich, Nuru |b 2 |
| 700 | 1 | _ | |a Bideak, Andrei |b 3 |
| 700 | 1 | _ | |a Müller, Martin B |b 4 |
| 700 | 1 | _ | |a Hoppe, John M |b 5 |
| 700 | 1 | _ | |a Gröne, Hermann-Josef |0 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91 |b 6 |u dkfz |
| 700 | 1 | _ | |a Locati, Massimo |b 7 |
| 700 | 1 | _ | |a Vielhauer, Volker |b 8 |
| 773 | _ | _ | |a 10.1016/j.ajpath.2018.09.016 |g p. S0002944017311495 |0 PERI:(DE-600)1480207-7 |n 2 |p 231-247 |t The American journal of pathology |v 189 |y 2019 |x 0002-9440 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:141759 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 6 |6 P:(DE-He78)00a2ea610aee4a8fca32908fc3d02e91 |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-317 |2 G:(DE-HGF)POF3-300 |v Translational cancer research |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2019 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b AM J PATHOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)G130-20160331 |k G130 |l Zelluläre und Molekulare Pathologie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)G130-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|